publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
model
pleas
cite
articl
lin
q
et
al
durat
serum
neutral
antibodi
lesson
sarscov
infect
journal
microbiolog
immunolog
infect
http
doipleas
cite
articl
lin
q
et
al
durat
serum
neutral
antibodi
lesson
sarscov
infect
journal
microbiolog
immunolog
infect
http
doi
durat
serum
neutral
antibodi
lesson
sarscov
infect
dear
editor
novel
coronaviru
design
sever
acut
respiratori
syndrom
coronaviru
outbreak
pose
sever
threat
public
health
epidemiolog
clinic
featur
novel
cov
infect
elucid
studi
number
recov
patient
coronaviru
diseas
continu
increas
critic
issu
arous
wide
concern
patient
recov
reinfect
answer
question
great
help
followup
convalesc
patient
control
epidem
illustr
pathogen
seem
similar
sarscov
way
besid
recent
studi
show
neutral
antibodi
convalesc
sar
patient
could
block
enter
target
cell
vitro
impli
potenti
crossprotect
epitod
two
virus
thu
potenti
immun
protect
reinfect
may
share
common
featur
convalesc
sarscov
protect
specif
ab
includ
immunoglobulin
g
igg
ab
neutral
ab
nab
produc
b
cell
infect
viru
block
viru
enter
host
cell
defens
viral
reinfect
cohort
studi
convalesc
sarscov
patient
case
beij
hospit
arm
forc
polic
china
reveal
specif
igg
ab
nab
highli
correl
peak
month
onset
diseas
decreas
gradual
thereaft
fig
sinc
titer
decreas
markedli
month
igg
ab
nab
remain
detect
patient
throughout
year
followup
except
last
visit
month
sampl
turn
neg
cao
et
al
extend
followup
time
year
igg
ab
nab
detect
respect
month
anoth
studi
case
shanxi
design
sar
hospit
china
show
similar
result
serum
sampl
igg
ab
posit
day
onset
symptom
sarscov
posit
rate
increas
gradual
reach
day
remain
unchang
day
patient
respect
detect
year
notabl
year
later
convalesc
patient
still
sarscov
specif
igg
ab
longest
followup
studi
case
beij
china
show
patient
recov
patient
sustain
low
level
specif
igg
ab
sarscov
find
suggest
immun
respons
specif
ab
maintain
recov
sarscov
patient
year
sinc
sarscov
epidem
year
ago
specif
igg
ab
sarscov
may
wan
surviv
patient
could
suffici
protect
challeng
infect
howev
previou
experiment
sarscov
vaccin
neutral
antibodi
could
novel
prevent
therapeut
option
besid
day
reach
day
patient
acquir
specif
sarscov
ab
earli
period
recoveri
highlight
import
detect
ab
titer
convalesc
patient
otherwis
patient
low
titer
ab
may
effici
clearanc
experi
sarscov
expect
implic
treatment
manag
surveil
patient
research
support
nation
natur
scienc
foundat
china
